Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
NVDA -0.4EWJ 0.37TECK.B.TO -2.09CNQ.TO 0.71HHL.TO 0.075SYLD 0.03HAC.TO 0.04TRU -0.01
Amgen Inc. (AMGN)

NASDAQ:AMGN

Amgen Inc. (AMGN)

336.13
-1.47 (0.44%)
as of Jun 18, 2026, 10:19:00 pm Market Open.
47 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
PAST TOP PICK

Amgen Inc.(AMGN)

Jan 18, 2024
(A Top Pick Aug 08/23, Up 17%)

One of those you just buy today and hold. Pretty volatile. Secular trend in healthcare. Wide moat. 30% free cashflow. Good stock.

Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSI
Owned
Unlock Rating
$303.79

Stock price when the opinion was issued

$336.13

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Oct 02, 2023
A big gainer in Q3

They bought a pharma company, luckily wasn't blocked by the FTC. Shares jumped 21% in Q3.

Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$266.31

Stock price when the opinion was issued

$336.13

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Aug 17, 2023

His choice in the biotech space.

Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$265.73

Stock price when the opinion was issued

$336.13

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Aug 11, 2023

He took some money out of tech and put it into healthcare, which has seen an increase lately. He just added Amgen who delieverd a terrific report. He will continue to rally in the second half this year, will outperform tech.

Photo of Bill Baruch, Founder, Blue Line CapitalBill Baruch, Founder, Blue Line Capital
Owned
Unlock Rating
$262.45

Stock price when the opinion was issued

$336.13

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Aug 08, 2023

A long-term fine business and just reported good earnings. It's not in tech or industrials, so it has more stickiness. They made positive plans in their drug pipeline. Seasonally, now is the right time to buy biotech

(Analysts’ price target is $256.05)
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSI
Owned
Unlock Rating
$261.69

Stock price when the opinion was issued

$336.13

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Jul 28, 2023

He bought it last week to diversify and get more exposure in pharmaceuticals. They report next week. Compare to Abbvie which just surprised with drug sales. There's some FT overhang, but shares have been bottoming out recently. If they announce good results, investors will chase this next week.

Photo of Bill Baruch, Founder, Blue Line CapitalBill Baruch, Founder, Blue Line Capital
Owned
Unlock Rating
$236.86

Stock price when the opinion was issued

$336.13

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Amgen Inc.(AMGN)

Apr 28, 2023

Facing a patent crisis as proprietary tech is challenged.
Shares have recently sold off.
Will take time to see how prospects play out.
Good hold, but other places to invest for new investors. 

Photo of Darren SissonsDarren Sissons
No
Unlock Rating
$239.76

Stock price when the opinion was issued

$336.13

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Jan 11, 2023
Granddaddy of biotech. Even better than it used to be. Very deep bench of drugs. New acquisition will add growth on top of already-decent growth. Very strong financials. Income opportunity, stability, and some growth not yet fully priced in. Yield is 3.14%, well covered at 42%, increased by 11% average annually over 5 years. (Analysts’ price target is $268.80)
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$272.35

Stock price when the opinion was issued

$336.13

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Dec 28, 2022
Share have given up a lot since its Horizon Therapeutics deal, making it an opportunity.
Photo of Guy AdamiGuy AdamiUnlock Rating
$261.42

Stock price when the opinion was issued

$336.13

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Dec 12, 2022
Today, they said they are buying Horizon Therapeutics for $27.8 billion. This deal should close quickly, since there's little overlap of these companies' drugs. Initially, he thought the price was high, but now he likes the deal. An established, big biotech that bought a younger biotech with exciting drugs at a 15% premium. Amgen wants HT's portfolio of drugs treating rare diseases and well-covered by insurance, therefore lucrative. HT's drugs will benefit from Amgen's worldwide distribution.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$275.24

Stock price when the opinion was issued

$336.13

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Amgen Inc.(AMGN)

Oct 11, 2022
(A Top Pick Nov 01/21, Up 20%) Bought it to be defensive for 2022. They announced a new facility in San Francisco. The future looks positive.
Photo of Andrew PyleAndrew Pyle
Owned
Unlock Rating
$246.26

Stock price when the opinion was issued

$336.13

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Amgen Inc.(AMGN)

Oct 11, 2022
(A Top Pick Nov 01/21, Up 20%) Bought it to be defensive for 2022. They announced a new facility in San Francisco. The future looks positive.
Photo of Andrew PyleAndrew Pyle
Owned
Unlock Rating
$246.26

Stock price when the opinion was issued

$336.13

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Amgen Inc.(AMGN)

Sep 15, 2022
(A Top Pick Nov 03/20, Up 4.1%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AMGN has triggered its stop at $228. To remain disciplined, we recommend covering the holding at this time.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$227.47

Stock price when the opinion was issued

$336.13

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Aug 15, 2022
Some of their key drugs are coming off patent, so he likes how they're making key buys of companies like CCXI, which would give Amgen exposure to drugs for auto-immune diseases and inflammatory conditions. CCXI has one drug on the market to treat blood vessel inflammation and a handful of phase 1 treatments including ulcerative colitis. The deal is good for Amgen.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$251.08

Stock price when the opinion was issued

$336.13

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Amgen Inc.(AMGN)

Apr 21, 2022
(A Top Pick Nov 03/20, Up 17.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AMGN is progressing well. We now recommend trailing up the stop (from $218) to $228.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$257.24

Stock price when the opinion was issued

$336.13

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
Showing 1 to 15 of 124 entries
The ultimate 360° Tracker Your financial life in one place, automatically

Amgen Inc. (AMGN) Frequently Asked Questions

What is Amgen Inc. stock symbol?

Amgen Inc. is a American stock, trading under the symbol AMGN (previously AMGN-Q on Stockchase) on the NASDAQ (AMGN). It is usually referred to as NASDAQ:AMGN or AMGN

Is Amgen Inc. a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on AMGN (previously AMGN-Q on Stockchase) on Stockchase. Read the latest expert commentary for Amgen Inc..

Is Amgen Inc. a good investment or a top pick?

Amgen Inc. was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2022-04-21. Read the latest stock experts ratings for Amgen Inc..

Why is Amgen Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Amgen Inc..

Is Amgen Inc. worth watching?

Amgen Inc. is followed by 47 investors on Stockchase and is a trending stock that is worth watching.

What is Amgen Inc. stock price?

On 2026-06-18, Amgen Inc. (AMGN) stock closed at a price of $336.13.

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

VEEV 0$153.3
WSP.TO 1.13$176.7
VRTX 0.47$452.1
OTEX.TO 0.24$29.47
CCO.TO 0.61$151.07

Today's Top Picks

NVDA -0.4$210.29
EWJ 0.37$96.63
TECK.B.T… -2.09$88.93
CNQ.TO 0.71$58.66
HHL.TO 0.075$6.865

Popular Articles

Latest Sell Signals

TD.TO 0.7$169.33
MBLY -0.03$8.43
ASAN 0.03$6.95
MODG -0.01$18.21
NVTS 0$24.02

Most Recent Experts

Stockchase Insights

Stockchase Insights

5i Research

Brian Acker, CA

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica